title: [A case of lacrimal duct obstruction caused by capecitabine].
abstract: In recent years, the incidence of adverse ocular reactions, including corneal problems and lacrimal duct obstruction, due to antineoplastic agents such as S-1 has increased. Very few reports of adverse ocular reactions caused by capecitabine, a fluorinated pyrimidine antineoplastic agent like S-1, exist, and consequently, the mechanism underlying these reactions is not well understood. This report describes our recent experience with a case of lacrimal duct obstruction caused by capecitabine. The patient was a 71-year-old woman who was being administered trastuzumab plus capecitabine combination chemotherapy for breast cancer-related bone metastasis. She complained of epiphora 7 days after capecitabine was initiated. Thereafter, her capecitabine dose was reduced owing to exacerbation of hand-foot syndrome, but the epiphora persisted. Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome. However, because the epiphora persisted, the patient visited the ophthalmology department. The ophthalmologist diagnosed the patient with binocular nasolacrimal duct obstruction and cataract, and prescribed a 0.3% gatifloxacin ophthalmic solution and 0.1% fluorometholone ophthalmic suspension. Thereafter, the epiphora reduced. When the patient returned to the ophthalmology department, symptom improvement was confirmed. In this case, lacrimal duct obstruction likely developed due to capecitabine. The symptoms were reversible with discontinuation of capecitabine and ophthalmic treatment. We believe that reporting this case could be valuable in discussing capecitabine-induced lacrimal duct obstruction.
authors.affiliation: Dept. of Pharmacy, Daini Okamoto General Hospital.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Noguchi
authors.forename: Takuya
authors.initials: T
authors.lastname: Mitani
authors.forename: Hiroko
authors.initials: H
authors.lastname: Kawara
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tokuyama
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Tamura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Shimizu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005469:Fluorometholone / Q000627:therapeutic use; D024841:Fluoroquinolones / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077734:Gatifloxacin; D060831:Hand-Foot Syndrome; D006801:Humans; D007767:Lacrimal Duct Obstruction / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D024841:Fluoroquinolones; D003841:Deoxycytidine; D000069287:Capecitabine; D000077734:Gatifloxacin; D005469:Fluorometholone; D005472:Fluorouracil